Ensysce Biosciences issued notice of allowance for MPAR tech patent

Ensysce Biosciences (ENSC) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a new patent covering Ensysce’s MPAR technology. The patent, titled “Compositions Comprising Enzyme-Cleavable Prodrugs and Controlled Release Nafamostat and Methods of Use Thereof”, includes both composition-of-matter and method-of-use claims that strengthen Ensysce’s intellectual property estate for its unique overdose protection platform. The new protection extends the Company’s MPAR patent coverage through 2042. MPAR, which earned Breakthrough Therapy Designation from the U.S. Food and Drug Administration in January 2025, is designed to limit the effects of opioid exposure in the event of an overdose. In clinical testing, PF614-MPAR demonstrated effective pain relief when taken as prescribed, while preventing excessive opioid delivery when multiple doses were administered. Beyond opioids, Ensysce is applying its MPAR technology to additional drug classes, including amphetamines and methadone, to develop safer treatments for pain, ADHD, and opioid use disorder.